Immunocore Holdings (IMCR) Debt to Equity (2019 - 2026)

Immunocore Holdings has disclosed Debt to Equity across 8 years of filings, most recently posting $1.0 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $1.0, down 3.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 (down 3.34% YoY), and the FY2025 annual result was $1.03, down 4.82% from the prior year.
• Debt to Equity came in at $1.0 for Q1 2026 at Immunocore Holdings, down from $1.03 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $1.22 in Q2 2024 to a low of $0.13 in Q4 2023.
• The 5-year median for Debt to Equity is $1.03 (2025), against an average of $0.9.
• Across the five-year window, Debt to Equity slumped 34.7% in 2022 and surged 732.77% in 2024, its largest moves.
• Immunocore Holdings' Debt to Equity stood at $0.14 in 2022, then dropped by 8.14% to $0.13 in 2023, then soared by 732.77% to $1.08 in 2024, then declined by 4.82% to $1.03 in 2025, then dropped by 3.08% to $1.0 in 2026.
• The last three Debt to Equity figures came in at $1.0 (Q1 2026), $1.03 (Q4 2025), and $0.99 (Q3 2025), per Business Quant data.